TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
An international genetic study analyzed data from about 2.8 million people and identified 127 DNA regions associated with Alzheimer’s risk, 48 of them newly mapped in this context. The findings highlight microglia and specific neuron types, but genetic associations do not prove cause or point directly to a treatment.
An international team has identified 127 regions of human DNA associated with Alzheimer’s disease risk, including 48 not previously mapped in this context, in a study drawing on genetic data from about 2.8 million people. Published in Nature, the research points to biological processes involving brain immune cells and specific types of neurons, offering researchers new leads to investigate—not proof of causes or ready-made treatments.
The study was led by Ole Andreassen of the University of Oslo and Oslo University Hospital with an international consortium. The analysis included 183,620 people with Alzheimer’s among approximately 2.8 million individuals. The researchers brought together data from 30 research groups, according to the report.
One prominent finding concerns microglia, immune cells in the brain that help clear harmful substances and damaged cellular material. The authors reported genetic evidence linked to microglial activation, the recruitment of immune cells, and the clearance of material in the brain. They also found associations involving amyloid processing, nerve-cell repair, astrocyte activation and maintenance of the insulating layer around nerve fibers.
The team also reported genetic signals enriched in several specific types of neurons. The source describes this as the first identification, in this study context, of several neuron types with such enriched signals. The findings may guide further research into how Alzheimer’s develops, but an association between a genetic region and risk does not establish that the region causes the disease.
The researchers estimated that common genetic variants together explain about 16% of differences in Alzheimer’s risk between people. The report says this is nearly three times earlier estimates of around 5%, with the revised estimate largely reflecting a statistical method that better accounts for APOE, a gene with an unusually large effect on risk. This is a population-level estimate, not the share of an individual’s disease attributable to genes.
New Leads Across Brain Cell Types
The results expand the set of genetic associations available for studying Alzheimer’s and link some of them to more specific biological processes. That can help research teams decide which genes and cell functions to examine in laboratory models, including processes involving microglia, neurons and supporting brain cells.
The work also adds evidence that common genetic variation accounts for more population-level differences in risk than some earlier estimates suggested. That does not mean genes alone determine who develops Alzheimer’s: age, environment and other biological and personal factors also matter, the researchers said. Nor does the estimate mean a genetic test can predict an individual’s future with certainty.
For treatment research, the findings are a source of possible targets, not evidence that changing any particular gene or process will safely prevent or treat the disease. Follow-up work must establish which associations have a causal role and whether acting on them would have a meaningful clinical effect.
Products Worth Considering
Therabody Theragun Prime 6th Generation Deep Tissue Massage Gun, Navy
Garmin Forerunner 55 GPS Running Smartwatch, Black
Garmin Forerunner 165 GPS Running Smartwatch, 43 mm, Black
As an affiliate, we earn on qualifying purchases.
How the Genetic Estimate Changed
Alzheimer’s is the leading cause of dementia, according to the source report. It notes projections that the number of people living with dementia worldwide could exceed 150 million by 2050. That forecast gives added weight to research aimed at understanding disease biology, though this genetic study does not itself change current prevention or treatment options.
Earlier estimates put the contribution of common genetic variants to differences in Alzheimer’s risk at about 5%. The authors’ estimate of roughly 16% is higher mainly because their statistical approach better accounts for APOE’s unusually large effect. The two figures describe population-level variation in risk; they are not measures of how much of a particular person’s illness is genetic.
Pooling data across research groups made it possible to analyze a much larger sample than any one group could typically assemble alone. The study’s scale and the inclusion of people from diverse genetic backgrounds, as described by a co-author, are central to the researchers’ claim that the analysis could reveal associations missed in smaller studies.
“This is the largest genetic association study on Alzheimer’s to date, bringing together data from individuals with diverse genetic backgrounds.”
— Alexey Shadrin, study co-author
Associations Are Not Causes
The study identifies genetic associations, but the source report says further research is needed to determine which findings play a causal role in Alzheimer’s. It remains unclear which of the newly mapped regions will lead to useful biological explanations, and whether any process identified can be safely changed to affect disease risk or progression.
The improved genetic risk prediction is described as relevant mainly to research at present. Whether such models could be used responsibly in clinical care remains unresolved. The findings also do not establish that genetic testing can determine whether a particular person will develop Alzheimer’s.
The supplied report does not provide detailed results for each of the 48 newly mapped regions, the effect size associated with each one, or the study’s full breakdown of participants by ancestry. Those details would help readers assess the strength and reach of individual findings; they cannot be inferred from the overall sample size.
Follow-Up Work on Candidate Targets
Researchers will need to test the reported associations in further studies and laboratory models to identify which signals reflect causal biology. The report says the results can help scientists build models for examining disease processes and nominate potential targets for future medicines.
Any proposed treatment direction would require additional evidence on whether intervening in a process is effective and safe. The study does not announce a clinical trial, a new diagnostic test or a change to patient care. For now, its clearest next step is further investigation of the genetic signals and the brain-cell processes they may involve.
Key Questions
What did the study find?
Researchers identified 127 DNA regions associated with Alzheimer’s risk, including 48 not previously mapped in this context. They also reported signals involving microglia, specific neuron types and other brain processes.
Does the study show that these genetic regions cause Alzheimer’s?
No. The findings are genetic associations. The researchers say further work is needed to establish which associations have a causal role and whether acting on them could affect the disease.
What does the 16% estimate mean?
It is an estimate of how much common genetic variants collectively explain differences in Alzheimer’s risk across people in a population. It does not mean genes account for 16% of an individual’s disease or that a test can determine whether someone will develop Alzheimer’s.
Can the findings lead to a new treatment?
They may help researchers select biological processes and potential targets for further study. The study does not show that targeting any of them will produce an effective or safe treatment.
Source: news-medical.net
